Patents by Inventor Derek Moe
Derek Moe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230301941Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.Type: ApplicationFiled: March 15, 2023Publication date: September 28, 2023Applicant: Clexio Biosciences Ltd.Inventors: Derek MOE, Randal SEBURG, Sagar RANE
-
Publication number: 20220175766Abstract: Pharmaceutical compositions are provided containing tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate or a pharmaceutically acceptable salt thereof, more particularly to certain orally deliverable immediate release solid pharmaceutical compositions containing a pharmaceutically acceptable salt of tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate and orally deliverable delayed release solid pharmaceutical compositions containing tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate or a pharmaceutically acceptable salt of. Also provided are methods and uses related to said compositions, as well as processes for the preparation of said compositions, and certain dosage regimens for the administration thereof.Type: ApplicationFiled: July 19, 2021Publication date: June 9, 2022Inventors: Barrett Levesque, Derek Moe, Nathaniel Santos Martinez
-
Patent number: 11324707Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.Type: GrantFiled: May 7, 2020Date of Patent: May 10, 2022Assignee: CLEXIO BIOSCIENCES LTD.Inventors: Derek Moe, Randal Seburg, Sagar Rane
-
Publication number: 20220105055Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.Type: ApplicationFiled: December 13, 2021Publication date: April 7, 2022Inventors: Derek Moe, Randal Seburg, Sagar Rane
-
Publication number: 20220062200Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.Type: ApplicationFiled: November 10, 2021Publication date: March 3, 2022Inventors: Derek MOE, Randal SEBURG, Sagar RANE
-
Publication number: 20200352881Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.Type: ApplicationFiled: May 7, 2020Publication date: November 12, 2020Inventors: Derek Moe, Randal Seburg, Sagar Rane
-
Patent number: 9974751Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.Type: GrantFiled: December 31, 2012Date of Patent: May 22, 2018Assignee: Cima Labs Inc.Inventors: Walid Habib, Ehab Hamed, Derek Moe, Carrie Kraling, Lisa Hillman
-
Patent number: 8298577Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: October 30, 2012Assignee: Cephalon, Inc.Inventor: Derek Moe
-
Patent number: 8119158Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: February 21, 2012Assignee: Cephalon, Inc.Inventors: Derek Moe, Vikas Agarwal, Walib Habib
-
Patent number: 8092832Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: January 10, 2012Assignee: Cephalon, Inc.Inventors: Derek Moe, Vikas Agarwal, Walib Habib
-
Publication number: 20110200681Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: CIMA LABS INC.Inventors: Walid Habib, Ehab Hamed, Derek Moe, Carrie Kraling, Lisa Hillman
-
Publication number: 20110073518Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: ApplicationFiled: November 29, 2010Publication date: March 31, 2011Applicant: CIMA LABS INC.Inventors: Derek Moe, Vikas Agarwal, Walid Habib
-
Publication number: 20110070169Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: ApplicationFiled: November 29, 2010Publication date: March 24, 2011Applicant: CIMA LABS INC.Inventors: Derek Moe, Vikas Agarwal, Walib Habib
-
Publication number: 20110071181Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.Type: ApplicationFiled: November 29, 2010Publication date: March 24, 2011Applicant: CIMA LABS INC.Inventor: Derek Moe
-
Patent number: 7862833Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.Type: GrantFiled: December 30, 2004Date of Patent: January 4, 2011Assignee: Cima Labs, Inc.Inventor: Derek Moe
-
Patent number: 7862832Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: December 30, 2004Date of Patent: January 4, 2011Assignee: Cima Labs, Inc.Inventors: Derek Moe, Vikas Agarwal, Walid Habib
-
Patent number: 7858121Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: December 30, 2004Date of Patent: December 28, 2010Assignee: Cima Labs, Inc.Inventors: Derek Moe, Vikas Agarwal, Walid Habib
-
Publication number: 20080069891Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.Type: ApplicationFiled: September 13, 2007Publication date: March 20, 2008Applicant: CIMA LABS, Inc.Inventors: Walid Habib, Ehab Hamed, Derek Moe
-
Publication number: 20080031944Abstract: This invention relates to orally disintegrable, lorazepam-containing dosage forms which are storage stable and disintegrable within about 90 seconds or less. In one embodiment, there is provided a storage stable, orally disintegrable dosage form comprising: protected lorazepam particles comprising lorazepam and polymeric material having a glass transition temperature of about 65° C. or above. Also disclosed is a method of producing a storage stable lorazepam containing tablet.Type: ApplicationFiled: August 2, 2007Publication date: February 7, 2008Applicant: CIMA LABS INC.Inventors: Larry Bereuter, David K. Brown, Derek Moe
-
Publication number: 20080031949Abstract: The present invention provides an orally dissolvable/disintegrable, lyophilized dosage form including a protected granulate comprising an active ingredient and a protective granulation binder, which substantially protects the form and/or attributes of a granulate and/or active ingredient, and participates in masking bad tasting active ingredients, such as sulfur-containing materials, and a matrix, and a method for making same. There is also provided a method of treating a patient using any orally dissolvable/disintegrable lyophilized dosage form comprising the steps of placing the dosage form in the mouth of a patient in need of treatment, allowing the dosage form to disintegrate/dissolve sufficiently to allow it, and in particular, the protected granulate, to be swallowed as a solution, suspension or slurry, and swallowing the at least partially disintegrated/dissolved dosage form.Type: ApplicationFiled: July 23, 2007Publication date: February 7, 2008Applicants: CIMA LABS INC., Cephalon FranceInventors: Ehab Hamed, Rajendra Khankari, Derek Moe, Thanh-Tam Nguyen